Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
21d
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...
Intellia Therapeutics shifts focus to NTLA-2002 for ... and initiating pre-approval discussions with payers. Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday.
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.
On Thursday, Intellia Therapeutics Inc (NASDAQ ... Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday. Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market ...
On Thursday, Intellia Therapeutics Inc (NASDAQ ... Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback